University of Southampton, UK
Coordinator: Prof Eugen Stulz, School of Chemistry.
OLIGOMED comprises 12 beneficiaries: 8 world-class academic units, 1 leading hospital unit, 2 high-quality SMEs, and 1 world-leading pharmaceutical company.
Find below the links to the individual beneficiaries; contact details can be found in the Contact Us page.
CNRS Marseille, FR
Dr Ling Peng, CINAM (UMR 7325)
Karolinska Institutet, SE
Prof Roger Strömberg, Department of Biosciences and Nutrition.
BioVectis, PL
Dr Krzysztof Kucharczyk, CEO, R&D
Stockholms Läns Landsting, SE
Prof Edvard Smith, Clinical Research Center at Karolinska University Hospital
Université de Bordeaux, FR
Prof Philippe Barthélémy, INSERM U1212 / UMR CNRS 5320
Universiteit Gent, BE
Prof Annemieke Madder, Organic and Biomimetic Chemistry Research Group
AstraZeneca, SE
Dr Shalini Andersson, Cardiovascular, Renal and Metabolic Diseases (CVRM)
Università degli Studi di Udine, IT
Dr Carlo Vascotto, School of Medicine
University of Cambridge, UK
Prof Florian Hollfelder, School of Biology
Research Institutes of Sweden RISE, SE
Dr Ulf Tedebark, Surface, Process and Formulation
Sixfold Bioscience, UK
Dr Anna Perdrix Rosell, Managing Director, R&D